Aprea Therapeutics, Inc. (NASDAQ:APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Global Select Market as set forth in Nasdaq Listing Rule 5450(a)(1) (“Min Bid Price Rule”).
“We are excited about regaining compliance and we believe our recent financing, which was supported by quality institutions, has strengthened our balance sheet and enabled the Company to continue developing its clinical asset, ATRN-119, and its pre-clinical asset ATRN-W1051” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics.
